leadf
logo-loader
viewImmuPharma PLC
(
AIM:IMM
)

ImmuPharma partner looks to streamline phase III approval process for lupus drug

The special assessment protocol is a process that decides on the design and size of the study that will both meet the scientific and regulatory requirements and supports marketing approval for new drugs such as Lupuzor

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM, FRA: 25I) has said its licensing partner has submitted a special protocol assessment (SPA) request to the US regulators ahead of a phase III clinical trial of its lupus drug.

The SPA is a process by which the US Food & Drug Administration and Avion Pharmaceuticals will decide on the design and size of the study that will both meet the scientific and regulatory requirements and supports marketing approval for Lupuzor.

The review period for an SPA request is up to 45 days, said ImmuPharma, which has been working with Avion to finalise a new optimised international protocol.

Poorly treated

Lupus is what’s called a systemic autoimmune disease that occurs when the body's immune system attacks its own tissues and organs.

Inflammation caused by lupus can affect many different systems, including joints, skin, kidneys, blood cells, brain, heart and lungs.

While, thankfully, it is rare, Lupus’ symptoms are painful and sometimes fatal.

The condition is poorly treated with only one bespoke drug for the condition – Benlysta, developed by GlaxoSmithKline. AstraZeneca is expected to add a second medication when it brings anifrolumab to the market next year.

Quick facts: ImmuPharma PLC

Follow
AIM:IMM

Price: 7.7 GBX

Market Cap: £19.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmuPharma’s CEO, Tim McCarthy, presents commercial strategy for lupus drug...

ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.  The study...

on 17/8/21

2 min read